'The big surprise here is the efficacy': UBS's Stuart Kaiser on market reaction to Pfizer vaccine reports

Stuart Kaiser, UBS Head of Equity Derivatives Research, joined Yahoo Finance Live to discuss today’s market action as investors digest the election results and COVID-19 vaccine news from Pfizer. …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.